Find, compare & contact
Midazolami (Midazolam)
API Manufacturers & Suppliers
To view suppliers for this material, you need to be logged in first.
This is because of international laws regarding narcotic materials. Furthermore, the contents of this page are only accessible if you are professionaly active in the pharmaceutical industry. In case you are, it is possible to register on our platform, and after your account is approved by our team you will be able to view suppliers and send your request.
Looking for Midazolam API 59467-70-8?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Midazolam. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Midazolam
- Synonyms:
- Buccolam , Dormicum , Midazolam , Midazolamum , Midazolami
- Cas Number:
- 59467-70-8
- DrugBank number:
- DB00683
- Unique Ingredient Identifier:
- R60L0SM5BC
About Midazolam
Why are people looking for Midazolam? Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called benzodiazepines. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazolam is available by oral, rectal, intranasal, intramuscular (IM), and intravenous (IV) routes and has been used in various biomedical applications, including dentistry, cardiac surgery, and endoscopic procedures as pre-anesthetic medication, and as an adjunct to local anesthesia.
This drug was initially approved by the US FDA in 1985, and has been approved for various indications since.
Do you want to buy this product? Send an inquiry to the listed suppliers that meets your quality requirements.
Midazolam is a type of Intravenous anesthetics
Intravenous anesthetics are a vital subcategory of pharmaceutical active pharmaceutical ingredients (APIs) used in medical procedures that require general anesthesia. These potent compounds are administered intravenously to induce a controlled state of unconsciousness, allowing patients to undergo surgeries or other invasive procedures without pain or discomfort.
One of the primary benefits of intravenous anesthetics is their rapid onset of action. These APIs quickly enter the bloodstream upon injection, facilitating a swift and predictable induction of anesthesia. Additionally, their potency allows for precise control of the depth of anesthesia, ensuring patient safety throughout the procedure.
Commonly used intravenous anesthetics include propofol, etomidate, and barbiturates. Propofol, for instance, is a short-acting agent that offers smooth and rapid induction and recovery, making it ideal for outpatient surgeries. Etomidate, on the other hand, provides hemodynamic stability and is commonly used in patients with cardiovascular conditions.
The use of intravenous anesthetics requires expertise and careful monitoring due to their potential side effects, such as respiratory depression and cardiovascular instability. However, their controlled and reversible nature allows for a tailored anesthesia experience, minimizing the risk of complications and ensuring patient comfort.
In summary, intravenous anesthetics are crucial pharmaceutical APIs used in anesthesia practice. Their rapid onset, precise control, and reversible effects make them essential tools for anesthesiologists, enabling safe and effective management of patients undergoing various medical procedures.
Midazolam (Intravenous anesthetics), classified under Anesthetics
Anesthetics are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) widely used in the field of medicine. These substances play a vital role in inducing a temporary loss of sensation or consciousness, enabling medical procedures to be performed without pain or discomfort. Anesthetics can be classified into two primary types: general anesthetics and local anesthetics.
General anesthetics act on the central nervous system, producing a reversible loss of consciousness. They are administered through inhalation or injection routes and are commonly employed for major surgeries or procedures that require deep sedation. Examples of general anesthetics include sevoflurane, propofol, and isoflurane.
On the other hand, local anesthetics primarily target a specific region or part of the body, temporarily numbing the area and blocking pain signals. These APIs are frequently used in dental procedures, minor surgeries, and childbirth. Common local anesthetics include lidocaine, bupivacaine, and ropivacaine.
Anesthetics work by interfering with the transmission of nerve signals or by altering the activity of certain receptors in the nervous system. They offer precise control over pain management, allowing medical professionals to perform complex procedures with reduced patient discomfort and anxiety.
The development and manufacturing of anesthetics APIs require stringent quality control measures to ensure safety and efficacy. Pharmaceutical companies adhere to strict regulatory guidelines to produce high-quality APIs. The demand for anesthetics remains consistently high, making this category of APIs a critical component of the pharmaceutical industry.
In conclusion, anesthetics are indispensable pharmaceutical APIs used to induce temporary loss of sensation or consciousness. They can be classified into general and local anesthetics, each serving distinct purposes in medical procedures. The proper development and manufacturing of anesthetics APIs are essential to ensure safe and effective pain management in various healthcare settings.
